8513.HK MaxWin Intl (HKSE) at HK$1.15 pre-market on high volume: outlook

8513.HK MaxWin Intl (HKSE) at HK$1.15 pre-market on high volume: outlook

The 8513.HK stock is trading at HK$1.15 in pre-market Hong Kong trade with volume 26,400 and relative volume 5.89x, marking a sharp move after a prior close of HK$0.12. This high-volume move on the HKSE deserves attention from liquidity-focused traders and investors because the jump changes short-term risk profiles and opens price discovery around the Year High HK$1.86 and Year Low HK$0.11. We outline valuation, technical signals, model forecasts and practical trading checks for MaxWin International Holdings Limited (8513.HK) in this pre-market note.

Pre-market price and volume for 8513.HK stock

MaxWin International Holdings Limited (8513.HK) is quoted at HK$1.15 on the HKSE in Hong Kong with reported volume 26,400 versus an average volume of 81,436. The intraday range so far is HK$1.15 to HK$1.15, reflecting an opening gap from the previous close of HK$0.12 and a large one-day percent change driven by low prior liquidity.

High relative volume and a large percent change often signal block trades, newsflow, or short-covering in small-cap names. Confirm order book depth before entering positions.

Fundamentals and valuation for 8513.HK stock

On reported metrics, 8513.HK shows EPS -0.09 and a trailing PE -1.22, reflecting losses. The company’s book and cash metrics show PB ~7.68 and current ratio 1.77, while debt-to-equity is 2.09, indicating leverage pressure relative to equity.

Market capitalisation is listed at HKD 9,003,009 with shares outstanding 81,845,538. Price averages are 50-day HK$1.23 and 200-day HK$1.33, frames useful for medium-term risk assessment and support/resistance planning.

Technical signals and short-term outlook for 8513.HK stock

Momentum indicators are mixed: RSI 36.40 and CCI -143.23 point to short-term oversold momentum after earlier swings, while ADX 16.12 signals no clear trend. Price sits below the 50- and 200-day averages, so follow-through is needed to confirm strength.

For traders, watch immediate support near the prior float levels and a failure below HK$0.60 would increase downside risk. A break and hold above HK$1.50 would be a short-term bullish trigger.

Meyka AI rates 8513.HK with a score out of 100 and model forecast

Meyka AI rates 8513.HK with a score out of 100: 61.53 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Grades are informational and not financial advice.

Meyka AI’s forecast model projects a yearly price HK$0.04, implying -96.18% versus the current HK$1.15. The monthly model shows HK$0.10 (implied -91.30%). Forecasts are model-based projections and not guarantees; use them alongside company updates and liquidity checks.

Catalysts, risks and sector context for 8513.HK stock

Key catalysts include the scheduled earnings announcement on 2026-03-25 and any contract wins in medical equipment or tooling services. Sector peers in Healthcare have delivered YTD strength, which can lift sentiment if MaxWin reports improving margins.

Main risks are high leverage, negative EPS, thin free cash flow, and low liquidity that can magnify moves. For competitor comparison and recent filings see Investing.com comparison and Reuters company metrics source.

Practical trading strategy for high-volume movers in 8513.HK stock

Given the high-volume pre-market move traders should size positions conservatively, use tight limits, and prefer limit orders to manage slippage. Monitor order-book depth and block trades to distinguish headline-driven spikes from structural demand.

Scenario targets: Bear HK$0.20 (down -82.61%), Base HK$0.80 (down -30.43%), Bull HK$1.80 (up 56.52%) from HK$1.15. Adjust stop-loss and take-profit levels to your risk profile.

Final Thoughts

High pre-market volume has pushed 8513.HK stock to HK$1.15 on the HKSE, changing the immediate liquidity picture and making intraday order-flow the primary driver. Fundamentals show negative EPS (-0.09), a negative PE, high PB ~7.68, and elevated debt-to-equity 2.09, which increases sensitivity to revenue swings. Technical indicators (RSI 36.40, CCI -143.23) are biased toward short-term oversold, but ADX 16.12 shows no confirmed trend. Meyka AI’s forecast model projects a yearly price of HK$0.04, an implied decline of -96.18% versus today, and our scenario targets range from a bear HK$0.20 to a bull HK$1.80. Use tight risk controls, confirm catalysts such as the 2026-03-25 earnings date, and treat short-term moves as liquidity events rather than valuation validation. Meyka AI provides this as AI-powered market analysis; forecasts and the Meyka grade are model outputs and not guarantees.

FAQs

What caused the pre-market jump in 8513.HK stock?

The pre-market rise to HK$1.15 came with volume 26,400 and likely reflects low-float trading, block orders, or short-covering. No single confirmed corporate announcement is in the public filings yet; always verify with filings and order-book data.

How does Meyka AI rate 8513.HK stock?

Meyka AI rates 8513.HK with a score out of 100: 61.53 (Grade B, HOLD). The grade combines benchmark, sector, financial growth, metrics and forecasts. This is informational, not investment advice.

What is the short-term technical outlook for 8513.HK stock?

Short-term indicators show RSI 36.40 and CCI -143.23, suggesting oversold conditions but no clear trend (ADX 16.12). Traders should wait for volume-confirmed breaks above HK$1.50 or below key support levels before adding size.

What are realistic price targets and forecasts for 8513.HK stock?

Scenario targets: Bear HK$0.20, Base HK$0.80, Bull HK$1.80. Meyka AI’s model projects yearly HK$0.04 (model-based). Targets are projections, not guarantees; adjust for liquidity and upcoming earnings.

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *